Please login to the form below

Not currently logged in
Email:
Password:

Juno

This page shows the latest Juno news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts IO presence with Immatics deal

Celgene boosts IO presence with Immatics deal

It also  acquired CAR-T specialist Juno therapeutics for $9bn in 2018, giving it rights to lead CAR-T candidate JCAR017 (lisocabtagene maraleucel).

Latest news

More from news
Approximately 11 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Celgene and Juno hope to crash the party soon with JCAR017, armed with positive data in diffuse large B-cell lymphoma (DLBCL).

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    $9bn  acquisition of Juno.

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch November 2016 Deal Watch November 2016

    Winding back two years, Juno enjoyed the biggest Nasdaq IPO of 2014 raising around $265m at $24 per share. ... At the end of this November Juno shares were trading at around $20 per share and to date they have not recovered.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report directly to Hans Bishop, Juno’s president ... She said: “I am delighted to join Juno, a company that reflects my

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics